Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus SYNACORT.
DEXACORT vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid